1,667 reports of this reaction
1.4% of all SITAGLIPTIN reports
#20 most reported adverse reaction
PANCREATIC CARCINOMA is the #20 most commonly reported adverse reaction for SITAGLIPTIN, manufactured by Merck Sharp & Dohme LLC. There are 1,667 FDA adverse event reports linking SITAGLIPTIN to PANCREATIC CARCINOMA. This represents approximately 1.4% of all 119,503 adverse event reports for this drug.
SITAGLIPTIN has an overall safety score of 78 out of 100. Patients taking SITAGLIPTIN who experience pancreatic carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCREATIC CARCINOMA is a less commonly reported adverse event for SITAGLIPTIN, but still significant enough to appear in the safety profile.
In addition to pancreatic carcinoma, the following adverse reactions have been reported for SITAGLIPTIN:
The following drugs have also been linked to pancreatic carcinoma in FDA adverse event reports:
PANCREATIC CARCINOMA has been reported as an adverse event in 1,667 FDA reports for SITAGLIPTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCREATIC CARCINOMA accounts for approximately 1.4% of all adverse event reports for SITAGLIPTIN, making it a notable side effect.
If you experience pancreatic carcinoma while taking SITAGLIPTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.